(Updated - August 8, 2022 5:11 AM EDT)

JPMorgan analyst Anupam Rama downgraded Elevation Oncology (NASDAQ: ELEV) from Overweight ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE